Sarepta Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sarepta Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $442.93M | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $399.36M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | $611.09M | Mar 2, 2026 |
| FY2025 | Mar 31, 2025 | $744.86M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $658.41M | Mar 2, 2026 |
| FY2025 | Sep 30, 2024 | $467.17M | Mar 2, 2026 |
| FY2025 | Jun 30, 2024 | $362.93M | Mar 2, 2026 |
| FY2025 | Mar 31, 2024 | $413.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.24B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $933.01M | Feb 28, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.86B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.79B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.14B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $843.77M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $612.40M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $122.64M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $121.43M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $111.34M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $100.45M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $100.11M | Mar 1, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.10M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $219.27M | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | $360.57M | Mar 2, 2026 |
| FY2025 | Mar 31, 2025 | $473.96M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $505.85M | Mar 2, 2026 |
| FY2025 | Sep 30, 2024 | $338.08M | Mar 2, 2026 |
| FY2025 | Jun 30, 2024 | $316.00M | Mar 2, 2026 |
| FY2025 | Mar 31, 2024 | $308.93M | Mar 2, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($412.23M) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | ($50.57M) | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | $196.89M | Mar 2, 2026 |
| FY2025 | Mar 31, 2025 | ($447.51M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $159.05M | Mar 2, 2026 |
| FY2025 | Sep 30, 2024 | $33.61M | Mar 2, 2026 |
| FY2025 | Jun 30, 2024 | $6.46M | Mar 2, 2026 |
| FY2025 | Mar 31, 2024 | $36.12M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($535.98M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($703.49M) | Feb 28, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($699.78M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $218.08M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($267.82M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($536.20M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($459.71M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($170.72M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($137.07M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($138.35M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($118.03M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($230.22M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $207.24M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $190.44M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $188.52M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $136.14M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $223.14M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $133.95M | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | $113.27M | Mar 1, 2021 |
| FY2020 | Mar 31, 2019 | $90.55M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $146.21M | Feb 26, 2020 |
| FY2019 | Sep 30, 2018 | $86.58M | Feb 26, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.72M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $557.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $481.87M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $451.42M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $282.66M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $86.05M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $75.37M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $73.69M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $82.77M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $81.42M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($205.48M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($205.79M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($500.99M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($325.35M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($443.17M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $107.47M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($456.46M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($388.66M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($232.00M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($245.82M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.97M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $136.96M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $76.11M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $30.82M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $38.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $82.20M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $59.63M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $61.16M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $12.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $5.34M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.35B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.96B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $3.26B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.13B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.15B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.98B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.82B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.64B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.31B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $424.10M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.21B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $2.44B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $2.41B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.74B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.22B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.22B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.00B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $609.80M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $518.75M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $87.41M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $859.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $384.95M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $928.01M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $761.76M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $818.19M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $1.03B | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $789.22M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $336.69M | Feb 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.88B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($4.21B) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($4.45B) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($3.91B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($3.21B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.85B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($2.29B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($1.58B) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($1.22B) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.17B) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $801.28M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $428.43M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $966.78M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.12B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.50B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $835.08M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $370.83M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $599.69M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $122.42M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $828.97M | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | $140.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.24B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.54B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $563.67M | Feb 28, 2023 |
| FY2018 | Dec 31, 2018 | $420.55M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $431.05M | Feb 28, 2019 |
| FY2016 | Dec 31, 2016 | $17.67M | Feb 28, 2017 |
| FY2015 | Dec 31, 2015 | $26.84M | Feb 25, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Mar 2, 2026 |
| FY2025 | Mar 31, 2025 | (4) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 28, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 2, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Mar 31, 2025 | (4) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 104.96M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 96.90M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 93.73M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 87.95M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 87.13M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 79.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 75.18M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 71.07M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 64.79M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 54.76M | Mar 1, 2018 |